	US 12,130,281 B2
	Gene editing through microfluidic delivery
Armon R. Sharei, Cambridge, MA (US); Marc Lajoie, Seattle, WA (US); Klavs F. Jensen, Lexington, MA (US); and Robert S. Langer, Newton, MA (US)
Assigned to Massachusetts Institute of Technology, Cambridge, MA (US); and President and Fellows of Harvard College, Cambridge, MA (US)
Filed by Massachusetts Institute of Technology, Cambridge, MA (US); and President and Fellows of Harvard College, Cambridge, MA (US)
Filed on Aug. 17, 2021, as Appl. No. 17/404,286.
Application 17/404,286 is a division of application No. 15/542,892, granted, now 11,125,739, previously published as PCT/US2016/013113, filed on Jan. 12, 2016.
Claims priority of provisional application 62/102,347, filed on Jan. 12, 2015.
Prior Publication US 2022/0091099 A1, Mar. 24, 2022
Int. Cl. G01N 33/487 (2006.01); C12N 15/87 (2006.01); G01N 33/50 (2006.01); C12Q 1/00 (2006.01)

CPC G01N 33/5002 (2013.01) [C12N 15/87 (2013.01); G01N 33/48721 (2013.01); C12Q 1/00 (2013.01)]

23 Claims

1. A microfluidic system for delivering a complex comprising a protein and a nucleic acid (protein-nucleic acid complex) into a cell, comprising: (a) at least one microfluidic channel and (b) a protein-nucleic acid complex, wherein the at least one microfluidic channel comprises a cell-deforming constriction having a diameter that is 20-99% of the diameter of the cell and allows the delivery of the protein-nucleic acid complex in an intact form.